Quantification of Epstein-Barr virus DNA in patients undergoing SMILE chemotherapy for stage IV or relapsed/refractory extranodal NK/T-cell lymphoma

Quantification of Epstein-Barr virus DNA in patients undergoing SMILE chemotherapy for stage IV or relapsed/refractory extranodal NK/T-cell lymphoma - Quantification of Epstein-Barr virus DNA in patients undergoing SMILE chemotherapy for stage IV or relapsed/refractory extranodal NK/T-cell lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000741

Enrollment

Registered

2007-06-18

Start date

2007-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

untreated stage IV or relapsed/refractory NK/T-cell lymphoma

Interventions

SMILE chemotherapy (steroid, methotrexated, ifosfamide, l-asparaginase, etoposide)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Eligible to the phase II study of SMILE 2) Written informed consent to this additional study

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Disappearance rate of EBV-DNA after two cycles of the SMILE quantified by whole blood method	—

Secondary

Measure	Time frame
Disapperance rate of EBV-DNA after completion of intended therapy, prognostic value of EBV-DNA level, comparison between two methods of EBV-DNA quantification (whole blood vs plasma)	—

Countries

Japan

Contacts

Public ContactRitsuro Suzuki

Nagoya University School of Medicine Department of HSCT Data Management

r-suzuki@med.nagoya-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026